Are USPH insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies USPH leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Stock Ratings / Health Care / USPH / insiders

INNV (52) OMDA (53) PNTG (64) TDOC (55) ⌘ Pro Terminal →

U.S. Physical Therapy Inc. (USPH) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$84.90 -1.08% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $84.94

U.S. Physical Therapy Inc. (USPH) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (19.2% gross margin, 12% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $1.28B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on USPH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is USPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, U.S. Physical Therapy Inc. (NYSE: USPH) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $84.90 (-1.08% 1D, market cap $1.28B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, USPH ranks #77 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does USPH compare to INNV and OMDA in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), USPH carries a Roarable B- (70/100 RQD), trailing P/E of 32.6x, gross margin of 19.2%, and ROIC of 11.5%. By comparison, INNV (InnovAge Holding Corp.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -10.2%, cap $1.25B) and OMDA (Omada Health Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -15.7%, cap $1.15B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for USPH?

▼

Per USPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000885978), U.S. Physical Therapy Inc. generated $781.0M in revenue (+16.3% YoY), $39.6M in net income, and $75.1M in free cash flow against $1.20B in total assets and $152.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $84.94 (+0.05%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 9.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for USPH)Realized 20D OHLCV Swing Band: ±6.5%

Deterministic 5-Pillar Attribution (70/100 Composite)

🔍 WHY USPH SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (21% of score)

FRED Regime × Technicals: 82% of 52W Range • RSI-14 at 51.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning13/20 pts (-7 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-7 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A-$85.44+1.8% Next Q

Q2 (-2Q)

Grade B+$87.02+0.4% Next Q

Q3 (-1Q)

Grade B$87.34-2.8% Next Q

Current

Grade B-$84.90+6.6% Hist 90D α

Trajectory: A- (78) → B- (70)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the USPH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 70/100 (B-) score, USPH faces multiple-compression risk if 32.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 16.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($83.15) or 200D SMA ($76.74) invalidates the momentum regime and cuts Target Base ($89.48) toward Bear Floor ($69.62).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $USPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “USPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 70%NO 30%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

USPH Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (USPH)

No recent open-market Form 4 cluster sales or emergency dumps flagged on USPH. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (USPH Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

USPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.71%▲ ASCENDING CHANNEL

2026-11-03O $86.57H $86.57L $84.90C $84.90VOL 146.4K

RES: $90.75SUP: $81.26SMA50: $83.15SMA200: $76.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

USPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 USPH Butterfly Map → + Track USPH →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

25.2%/yr Implied 5Y Growth

vs. +16.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on USPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for USPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for USPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (USPH)

Health Care Rank #77 of 1015 ⚔️ INNV vs USPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (USPH vs. INNV, OMDA, PNTG, TDOC)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, U.S. Physical Therapy Inc. (USPH) ranks #77 by composite RQD confidence (70/100, grade B-) and #324 by equity capitalization ($1.28B). Within this direct 5-issuer industry benchmark cohort, USPH leads on earnings valuation at 32.6x trailing P/E, while USPH leads on capital efficiency and profitability with 11.5% ROIC and 19.2% gross margin. USPH currently leads its immediate peer cohort in composite quantitative strength at 70/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
USPH ACTIVE U.S. Physical Therapy Inc.	B-	70/100	32.6x	19.2%	11.5%	-1.08%	$1.28B	Benchmark Subject
INNV InnovAge Holding Corp.	D+	52/100	—	18.0%	-10.2%	-2.94%	$1.25B	/innv-vs-usph →
OMDA Omada Health Inc.	D+	53/100	—	65.7%	-15.7%	-4.70%	$1.15B	/omda-vs-usph →
PNTG The Pennant Group Inc.	C	64/100	50.2x	—	11.0%	-2.78%	$1.46B	/pntg-vs-usph →
TDOC Teladoc Health Inc.	D+	55/100	—	—	-17.0%	+1.41%	$1.55B	/tdoc-vs-usph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000885978 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), U.S. Physical Therapy Inc. (USPH) reported GAAP revenue of $781.0M (+16.3% vs. FY2024 revenue of $671.3M , and +29.1% cumulative change since FY2023) , GAAP net income of $39.6M, operating cash flow of $75.1M, and free cash flow of $75.1M (+0.2% YoY). On the balance sheet, USPH closed FY2025 with $1.20B in total assets against $152.6M in total debt (Altman Z-Score: 2.94, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$781.0M	$39.6M	$75.1M	$75.1M	$1.20B	$152.6M
FY2024 (FY)	2024-12-31	$671.3M	$31.4M	$74.9M	$74.9M	$1.17B	$142.5M
FY2023 (FY)	2023-12-31	$604.8M	$28.2M	$82.0M	$82.0M	—	—

3. USPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is USPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does USPH compare to INNV and OMDA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for USPH?

Where is USPH trading relative to its 50-day, 200-day, and 52-week technical levels?

USPH last traded at $84.90 (-1.08% on volume of 334,728 shares), positioning the stock +2.10% above its 50-day simple moving average ($83.15) and +10.63% above its 200-day simple moving average ($76.74). Across its 52-week range of $58.19 to $90.94, USPH sits at the 81.6% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($79.38 to $90.42).

Direct Sub-Reports: USPH RQD Cockpit USPH 12M Forecast USPH Earnings & Move USPH Dividends & DRIP USPH Insiders & 13F USPH Whale Options USPH Profit Sankey USPH News & Why

ROARABLE RATING BRIEF • RQD 70/100 (B-) ✓ SEC XBRL & RQD VERIFIED

USPH — U.S. Physical Therapy Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

U.S. Physical Therapy Inc. (USPH) earns a live Roarable RQD composite score of 70/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $84.90 (-1.08% 1D, market capitalization $1.28B).

Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 11.5%, gross margin of 19.2%, operating margin of 11.1%, and free cash flow yield of 5.81%.
Whale 13F & Options Flow (13/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (15/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.94, Piotroski F-Score of 8/9, and Debt/Equity of 0.32x.

2. Business Model, Unit Margins & SEC Financial Trajectory

U.S. Physical Therapy Inc. Is a NYSE-listed issuer classified under the Health Care sector and Medical/Nursing Services industry,. Its market capitalization is $1.3B. Revenue figures appear in the financials section below.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), U.S. Physical Therapy Inc. (USPH) reported $781.0M in annual revenue (up from $671.3M in FY2024, +16.3% YoY) and $39.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($604.8M revenue, $28.2M net income) through FY2025, USPH scaled operating cash flow to $75.1M and free cash flow to $75.1M, backed by $1.20B in total assets against $152.6M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B- • RQD 70/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 5.81% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $58.19 – $90.94 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 32.6x trailing P/E and 16.3x EV/EBITDA against 11.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided data.

Key Question #1: Can USPH sustain or expand its 11.1% operating margin and 11.5% ROIC against Medical/Nursing Services peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $781.0M and free cash flow of $75.1M, how will capital allocation balance growth reinvestment against $152.6M in total debt?
Key Question #3: How sensitive is USPH's 27.4x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

USPH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for U.S. Physical Therapy Inc. (USPH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to USPH Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 21h ago

U.S. Physical Therapy, Inc. (USPH) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering U.S. Physical Therapy Inc. (USPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Us Physical Therapy Stock Price Forecast. Should You Buy USPH?

StockInvest.us report covering U.S. Physical Therapy Inc. (USPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

U.S. Physical Therapy (USPH) Stock May Be Overvalued As Sales Face The Test

Yahoo Finance report covering U.S. Physical Therapy Inc. (USPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH The Globe and Mail • 1d ago

3 Reasons USPH is risky and 1 stock to buy instead

The Globe and Mail report covering U.S. Physical Therapy Inc. (USPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 1d ago

U.S. Physical Therapy (USPH) Stock Looks Above Fair Value Despite Its 13% Five Year Fall

Simply Wall St report covering U.S. Physical Therapy Inc. (USPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

US Physical Therapy (USPH) Stock Price, News & Analysis

Stock Titan report covering U.S. Physical Therapy Inc. (USPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

U.S. Physical Therapy (USPH) Climbs 1.49% to $85.93, Sitting Midway Between Key Technical Levels - RTH Profile

https://www.siam.in/ report covering U.S. Physical Therapy Inc. (USPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH StockStory • 1d ago

3 Profitable Stocks We Find Risky

StockStory report covering U.S. Physical Therapy Inc. (USPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

USPH Bull vs. Bear Conversation Board — What's Your Call at $84.90?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON USPH 🐻 33% BEARISH CONVICTION

AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $112.44 (+31.0%)

📌 Pinned Debate

Per the Roarable RQD rating, the forensic balance sheet (Altman Z 2.94, Piotroski F 8/9, Debt/Equity 0.32) and macro-fit pillar (beta 1

Don't sleep on USPH's setup in Health Care. Per the Roarable RQD rating, the forensic balance sheet (Altman Z 2.94, Piotroski F 8/9, Debt/Equity 0.32) and macro-fit pillar (beta 1.0) support the verdict of Roarable Buy.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (70/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

Both sides have a point here — USPH's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $69.52 (-19.0%)

Spot @ $85.83

Trailing P/E of 32.6 and EV/EBITDA of 16.3 sit well above the 5.81% FCF yield, so valuation leaves limited margin for error.

Sitting on the sidelines or leaning short USPH above $85.83. Trailing P/E of 32.6 and EV/EBITDA of 16.3 sit well above the 5.81% FCF yield, so valuation leaves limited margin for error.. Until Fundamental Cash Engine (13/20) and FCF yield (5.81%) inflect higher, upside is capped near $90.94.